Home / Stocks / NVO

Novo Nordisk A/S (NVO, Pharmaceuticals) Stock Valuation & Fair Value Trading above fair value

Novo Nordisk A/S (NVO, Pharmaceuticals) trades at a blended P/E of 13.4, about 44% below its historical normal valuation, with a forward growth estimate of 1.1% and a PEG of 12.62. Analysts' one-year estimates have been hit 82% of the time.

No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.

DATA AS OF 2026-08-28

Blended P/E

13.4

Normal P/E

24.1

PEG

12.62

Fwd growth

1.1%

Div yield

2.8%

RSI (14)

44.9

Neutral

The Street vs SeerForecast

Wall Street's mean price target for NVO is $47.47 across 12 analysts, 4.1% above the current price. The average analyst rating is Hold. Our SeerForecast read of the same stock, formed without analyst targets: trading above fair value. When the two disagree, start your digging there.

Valuation flags

High PEG (12.6x)
Low growth forecast

Verdict history

tickerseer's rating moved from fairly valued (2026-06-14) to trading above fair value (2026-08-28).

Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-14P/E 12.5-48%Fairly valued

2026-06-16P/E 12.5-48%Fairly valued

2026-06-21P/E 12.5-48%Fairly valued

2026-07-02P/E 12.5-48%Fairly valued

2026-07-06P/E 12.5-48%Fairly valued

2026-07-09P/E 12.5-48%Fairly valued

2026-07-12P/E 12.5-48%Fairly valued

2026-07-13P/E 12.5-48%Fairly valued

2026-07-14P/E 12.5-48%Fairly valued

2026-07-20P/E 12.5-48%Fairly valued

2026-07-31P/E 15.0-38%Significantly overvalued

2026-08-03P/E 13.7-43%Trading above fair value

2026-08-07P/E 13.7-43%Trading above fair value

2026-08-10P/E 13.7-43%Trading above fair value

2026-08-14P/E 13.7-43%Trading above fair value

2026-08-17P/E 13.1-45%Trading above fair value

2026-08-21P/E 13.1-45%Trading above fair value

2026-08-24P/E 13.4-44%Trading above fair value

2026-08-27P/E 13.4-44%Trading above fair value

2026-08-28P/E 13.4-44%Trading above fair value ← now

Frequently asked questions

Is Novo Nordisk A/S stock overvalued?

At a blended P/E of 13.4 versus its historical normal P/E of 24.1, Novo Nordisk A/S trades about 44% below its typical valuation, with a PEG of 12.62 on 1.1% forward growth. tickerseer currently rates it trading above fair value.

What is Novo Nordisk A/S's fair value and PEG?

Novo Nordisk A/S trades at a blended P/E of 13.4 against a historical normal P/E of 24.1, a PEG of 12.62, and a forward growth estimate of 1.1%.

Has tickerseer's rating of Novo Nordisk A/S changed?

tickerseer's rating moved from fairly valued (2026-06-14) to trading above fair value (2026-08-28).

What is the analyst price target for Novo Nordisk A/S?

The mean Wall Street price target for Novo Nordisk A/S is $47.47 across 12 analysts, 4.1% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track NVO free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.